Navigation Links
Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors

ANN ARBOR, Mich., July 8 /PRNewswire/ -- NanoBio(R) Corp., a biopharmaceutical company focused on developing and commercializing novel products to prevent and treat infectious diseases, today announced the appointment of Daniel B. Dubin, M.D., to its board of directors.

Dr. Dubin currently serves as Vice Chairman and a Director at Leerink Swann, a leading healthcare and biotechnology investment banking firm.

"Dan's keen understanding of the life sciences investment banking field and his clinical experience as a dermatologist bring a dual perspective that will help us create value and distinction as an emerging company in the biotechnology sector," said James R. Baker Jr., founder and Chairman of NanoBio. "His expertise and informed perspective in the field of dermatology will greatly enhance the strategic positioning of our topical treatments for herpes labialis, onychomycosis and other dermatologic infections."

A Harvard-trained dermatologist, Dr. Dubin served as Ambulatory Medical Director of the dermatology practice at Brigham and Women's Hospital. In 1996, Dr. Dubin co-founded MEDACorp to provide life science companies and institutional investors with expert insight into the development and adoption of biopharmaceuticals, medical devices and diagnostics. When MEDACorp merged with Leerink Swann in 2001, Dr. Dubin became a Director at Leerink Swann and later assumed the position of Vice Chairman. Dr. Dubin also serves on the board of Eleme Medical, a cellulite treatment company.

NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several phase 1 and 2 clinical trials without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
2. Anesiva Appoints Daniel Janney to Board of Directors
3. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
4. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
7. OmniSonics Appoints J. Daniel Cole Chairman of the Board
8. PPD Names Daniel Darazsdi as Chief Financial Officer
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
11. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Post Your Comments:
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):